Big Partnerships Give Biotechs A Boost To Richer Exits
This article was originally published in Start Up
Executive Summary
Biotechs in recent years are more likely to fetch a higher acquisition price – practically the only way for investors to exit these days – if the company has previously signed a major alliance. But the partners aren't necessarily the ones buying.
You may also be interested in...
Validating the Validating Deal
With M&A exits on the minds of venture investors and management alike, the idea that a strategic alliance on an important project or platform application might dilute downstream acquisition value is a serious consideration for biotech firms. Yet an analysis of private biotech acquisitions from January 2005 through early September 2008 suggests that those firms that strike a strategic alliance prior to acquisition actually do much better, exit-wise, for their backers.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.